| 
The described invention uses for the first time a polysaccharide, hydroxyethyl starch (HES), for the controlled shielding/deshielding of polyplexes. Designing carriers for safe and efficient delivery of therapeutic genes offer great potential for in vitro gene transfection as well as the in vivo the treatment of many difficult-to cure diseases, such as metastatic cancer.
© psdesign1
|
Medical researchers at the Ludwig-Maximilians-University (LMU) have developed a facile method for the production of vaccines against multi-resistant bacterial strains: Multi-resistant bacteria that are unaffected by most conventional antibiotics are recognized as an ever growing danger to global health. Hospital-acquired infections are a lethal threat to patients whose already weakened condition makes them particularly vulnerable to these so-called killer germs. A team of researchers around Dr. Andreas Wieser and Professor Sören Schubert has now developed a method which allows strain-adapted vaccines that are specific for selected types of bacteria to be manufactured in a very short time.
|
Erika von Mutius, Professor of Pediatric Allergology at Ludwig-Maximilians-Universität München (LMU) and Senior Consultant at Dr. von Hauner Children’s Hospital, has won the most important research prize in Germany, the Leibniz Prize. The accolade, awarded by the German Research Society (DFG), is worth 2.5 million euros. Her findings about asthma and allergies as well as related genetic predispositions and living conditions give great insights for doctors and patients.
|
Drug Delivery: Effective pain management during trauma or orthopedic surgery as well as in post-operative treatment is essential for the patient´s wellbeing and a quick and successful recovery. It also plays an important role in the context of chronic limb pain. Commonly used treatment options exhibit a number of detrimental side effects. Available pain therapeutics such as local anesthetics also impair motor and sensory function and therefore hinder rehabilitation. Systemically (Within the Central Nervous System; CNS) applied opioids can cause sedation, nausea and respiratory depression. Locally applied hydrophilic opioid drugs (such as DAMGO or morphine) on the other hand could offer pain relieve without interfering with other neuronal types and without the unwanted side effects on the central nervous system. However, their use on nociceptive nerve fibers of the pripheral nervous system is currently prevented by the fact that they cannot pass the perineurial cell barrier around the peripheral nerve cells. An invention from the Julius-Maximilian Universität Würzburg and Leibniz Institute for Molecular Pharmacology (FMP) could now help to apply these opioid drugs in the peripheral nervous system and reduce sideeffects.
|
Protein test finds hidden molecule - Immunotherapy can be a successful treatment option for breast cancer patients. The method uses antibodies, which bind to the surface molecules of the tumor, hindering its growth. One of these antibodies targets the HER2 protein, which is not actually present in all variants of the tumor. Now researchers have developed a sensitive new diagnostic method that could allow more patients to benefit from the treatment. This new test also detects cancer cells that appear to be free of HER2 – but which do actually carry the molecule.
|
Materials scientists at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) were ranked among the best in the world according to the Quantitative Ranking of Engineering Disciplines (QRED) of the École Polytechnique Fédérale de Lausanne which placed FAU at number 10.
|
A combination therapy consisting of the protein G-CSF and a DPP-IV enzyme inhibitor regenerates damaged heart muscle tissue. The therapy developed and successfully tested on patients in a Phase II trial at the University of Munich Medical Center represents a novel approach for treating acute heart attacks. On behalf of the Ludwig-Maximilians-University in Munich (LMU), the Bayerische Patentallianz GmbH, the central patent and marketing agency for 28 Bavarian universities and universities of applied sciences, has now licensed the new technology to RECARDIO GmbH, an innovative drug development company.
|
A new start-up from the Ludwig-Maximilians-University (LMU) in Munich will receive funding by the Federal Ministry of Economics and Technology (BMWi). The new company is specializing on testing apps using the crowd.
|
Dominik Schillinger will be awarded the John Argyris Award for the development of a new method that can facilitate simulations in mechanical or civil engineering. It is the most prestigious award for young scientists in computational mechanics. Schillinger was a scholar of the Munich Centre of Advanced Computing and the International Graduate School of Science and Engineering (IGSSE) at the Technische Universität München (TUM).
Simulation model of a ship propeller. (Photo: TUM)
|
The Bavarian universities have once again taken top spots in the German Excellence Initiative for Cutting-Edge Research at Institutions of Higher Education. According to Bavarian State Minister Wolfgang Heubisch, the Bavarian universities will receive a total funding of 450 mio Euros from the BMBF (Federal Ministry of Education and Research). Get the details.
© Deutsche Forschungsgemeinschaft
